Emcure Pharmaceuticals Q1 net profit rises 41% at ₹215 crore, revenue up 16%

Emcure Pharmaceuticals announced its financial results for the quarter ended June 30, 2025 on Thursday, August 7. The company’s consolidated profit after tax (PAT) stood at ₹215 crore, reflecting a 41% year-on-year (YoY) increase. Revenue from operations rose 15.7% YoY to ₹2,101 crore. The company reported EBITDA growth of 20.1% YoY, with EBITDA margins improving to 19.2%.

The revenue growth was driven by a balanced contribution from both domestic and international markets. Sales from the domestic business came in at ₹995 crore, marking a 9.4% YoY rise. The company, in an exchange filing, attributed this growth to a solid performance across all key therapies, coupled with new initiatives in the dermatology and over-the-counter (OTC) segments.

The company’s international business recorded a 22% growth during the quarter, with all business segments contributing to the performance. According to the company, “Rest of the World business continued the healthy momentum growing 42%. The company’s Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%.”

Commenting on the performance, Emcure Pharmaceuticals CEO and Managing Director, Satish Mehta said, "We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets through in-licensing and in-house development."

He further said, "The expanded Sanofi partnership positions us well in the fast-growing metabolic segment."

On the way forward, he said, "We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins."

Shares of Emcure Pharmaceuticals ended 1.57% lower at ₹1,400 apiece on the NSE on Thursday, August 7. The stock opened at ₹1,412.90 per share.

The company's market capitalisation stands at ₹26,531 crore.

The stock has declined by 0.55% in the last five days. Over the last month, similarly, it has increased by 12.62%.

In the last six months, the stock has increased by 15.44%, while the year-to-date drop stands at 4.13%. The stock touched its 52-week high of ₹1,580 apiece on the NSE and it hit its 52-week low of ₹889.